KR102324672B1 - Composition comprising extract from liriope platyphylla and natural extract - Google Patents
Composition comprising extract from liriope platyphylla and natural extract Download PDFInfo
- Publication number
- KR102324672B1 KR102324672B1 KR1020150153435A KR20150153435A KR102324672B1 KR 102324672 B1 KR102324672 B1 KR 102324672B1 KR 1020150153435 A KR1020150153435 A KR 1020150153435A KR 20150153435 A KR20150153435 A KR 20150153435A KR 102324672 B1 KR102324672 B1 KR 102324672B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- cosmetic composition
- chrysanthemum
- ginseng
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 107
- 239000000284 extract Substances 0.000 title claims abstract description 92
- 241001532026 Liriope muscari Species 0.000 title description 2
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 20
- 235000008434 ginseng Nutrition 0.000 claims abstract description 10
- LGURYBCSJPXHTF-UHFFFAOYSA-N 2-(2,4-dichlorophenoxy)ethyl benzoate Chemical compound ClC1=CC(Cl)=CC=C1OCCOC(=O)C1=CC=CC=C1 LGURYBCSJPXHTF-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 9
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 7
- 235000008397 ginger Nutrition 0.000 claims abstract description 7
- 241000233855 Orchidaceae Species 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 239000002537 cosmetic Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 208000001840 Dandruff Diseases 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 210000004761 scalp Anatomy 0.000 claims description 17
- 210000002374 sebum Anatomy 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 13
- 230000003078 antioxidant effect Effects 0.000 claims description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- 230000000844 anti-bacterial effect Effects 0.000 claims description 10
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 10
- 241000208340 Araliaceae Species 0.000 claims description 9
- 241000234314 Zingiber Species 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 7
- 230000003658 preventing hair loss Effects 0.000 claims description 7
- 240000003243 Thuja occidentalis Species 0.000 claims description 5
- 235000008109 Thuja occidentalis Nutrition 0.000 claims description 5
- 239000002034 butanolic fraction Substances 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 241000723353 Chrysanthemum Species 0.000 claims 9
- 235000020710 ginseng extract Nutrition 0.000 claims 7
- 229940002508 ginger extract Drugs 0.000 claims 4
- 235000020708 ginger extract Nutrition 0.000 claims 4
- 240000006859 Jasminum officinale Species 0.000 claims 1
- 235000010254 Jasminum officinale Nutrition 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 210000004209 hair Anatomy 0.000 description 29
- 238000009472 formulation Methods 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- 239000000523 sample Substances 0.000 description 23
- 201000004384 Alopecia Diseases 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 14
- 230000002500 effect on skin Effects 0.000 description 14
- 239000001301 oxygen Substances 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 13
- 230000003676 hair loss Effects 0.000 description 13
- 208000024963 hair loss Diseases 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 240000005250 Chrysanthemum indicum Species 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- -1 Ophiopogonon AE Natural products 0.000 description 8
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 8
- 230000007760 free radical scavenging Effects 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 230000002000 scavenging effect Effects 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 231100000360 alopecia Toxicity 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000003780 hair follicle Anatomy 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 230000003656 anti-hair-loss Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 230000003779 hair growth Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 229960005323 phenoxyethanol Drugs 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003809 water extraction Methods 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000003024 Diffuse alopecia Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 201000001297 telogen effluvium Diseases 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- MNAZQDBGIVJQLS-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-ylmethyl)-5,7-dihydroxy-6-methyl-4-oxochromene-8-carbaldehyde Chemical compound C1=C2OCOC2=CC(CC2=COC3=C(C=O)C(O)=C(C(=C3C2=O)O)C)=C1 MNAZQDBGIVJQLS-UHFFFAOYSA-N 0.000 description 2
- RIGYMJVFEJNCKD-UHFFFAOYSA-N Artemetin Chemical compound C1=C(OC)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(OC)C=C2O1 RIGYMJVFEJNCKD-UHFFFAOYSA-N 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000234280 Liliaceae Species 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 241000218213 Morus <angiosperm> Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- 201000002996 androgenic alopecia Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910001431 copper ion Inorganic materials 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 229940100242 glycol stearate Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- DFIGJQXADDYWIO-UHFFFAOYSA-N n-ethyltetradecan-1-amine Chemical compound CCCCCCCCCCCCCCNCC DFIGJQXADDYWIO-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical class O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000001965 potato dextrose agar Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 229940057950 sodium laureth sulfate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- YDDUMTOHNYZQPO-UHFFFAOYSA-N 1,3-bis{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid Natural products OC1C(O)CC(C(O)=O)(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- YFVGIJBUXMQFOF-PJOVQGMDSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 YFVGIJBUXMQFOF-PJOVQGMDSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- KLKARCOHVHLAJP-UWJYBYFXSA-N Ala-Tyr-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(O)=O KLKARCOHVHLAJP-UWJYBYFXSA-N 0.000 description 1
- 241000239223 Arachnida Species 0.000 description 1
- 235000015701 Artemisia arbuscula Nutrition 0.000 description 1
- 235000002657 Artemisia tridentata Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- DGKCOYGQLNWNCJ-ACZMJKKPSA-N Asp-Glu-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O DGKCOYGQLNWNCJ-ACZMJKKPSA-N 0.000 description 1
- SDTFURCSGWUESP-UHFFFAOYSA-N Bonanzin Natural products C1=C(OC)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(O)C=C2O1 SDTFURCSGWUESP-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 241000212948 Cnidium Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- SITQVDJAXQSXSA-CEZRHVESSA-N Cynarin Natural products O[C@@H]1C[C@@](C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)(OC(=O)C=Cc3cccc(O)c3O)C(=O)O SITQVDJAXQSXSA-CEZRHVESSA-N 0.000 description 1
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 description 1
- 241000234646 Cyperaceae Species 0.000 description 1
- 244000075634 Cyperus rotundus Species 0.000 description 1
- 235000016854 Cyperus rotundus Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229930188631 Eclalbasaponin Natural products 0.000 description 1
- 244000286838 Eclipta prostrata Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000644323 Escherichia coli C Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- DBUNRZUFILGKHP-UHFFFAOYSA-N Kuwanon A Natural products C1=CC(C)(C)OC2=C1C(O)=CC=C2C1=C(CC=C(C)C)C(=O)C2=C(O)C=C(O)C=C2O1 DBUNRZUFILGKHP-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- YFVGIJBUXMQFOF-SAXLCNSLSA-N Linarin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 YFVGIJBUXMQFOF-SAXLCNSLSA-N 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930195210 Ophiopogon Natural products 0.000 description 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 240000002924 Platycladus orientalis Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 241001073567 Verbenaceae Species 0.000 description 1
- 241000532412 Vitex Species 0.000 description 1
- 241000989077 Vitex rotundifolia Species 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- HTRXGEPDTFSKLI-UHFFFAOYSA-N butanoic acid;ethyl acetate Chemical compound CCCC(O)=O.CCOC(C)=O HTRXGEPDTFSKLI-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000009347 chasteberry Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000034557 congenital alopecia Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- YRUMDWGUXBZEPE-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1.C1CCCCC1 YRUMDWGUXBZEPE-UHFFFAOYSA-N 0.000 description 1
- 229950009125 cynarine Drugs 0.000 description 1
- YDDUMTOHNYZQPO-BKUKFAEQSA-N cynarine Natural products O[C@H]1C[C@@](C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O YDDUMTOHNYZQPO-BKUKFAEQSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000002849 elastaseinhibitory effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 230000003781 hair follicle cycle Effects 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- JQOAQUXIUNVRQW-UHFFFAOYSA-N hexane Chemical compound CCCCCC.CCCCCC JQOAQUXIUNVRQW-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229930184898 kuwanon Natural products 0.000 description 1
- APPXYONGBIXGRO-AIQWNVMPSA-N kuwanone G Chemical compound O=C([C@H]1[C@@H](CC(C)=C[C@@H]1C1=C2OC(=C(C(C2=C(O)C=C1O)=O)CC=C(C)C)C=1C(=CC(O)=CC=1)O)C=1C(=CC(O)=CC=1)O)C1=CC=C(O)C=C1O APPXYONGBIXGRO-AIQWNVMPSA-N 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical group C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940107889 rogaine Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 229930002600 steroidal saponin Natural products 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XQDCKJKKMFWXGB-UHFFFAOYSA-N wedelolactone Chemical compound O1C2=CC(O)=C(O)C=C2C2=C1C1=C(O)C=C(OC)C=C1OC2=O XQDCKJKKMFWXGB-UHFFFAOYSA-N 0.000 description 1
- RFQPHWCAHNTCDX-UHFFFAOYSA-N wedelolactone Natural products COc1cc(O)cc2OC(=O)c3c(oc4cc(O)c(O)cc34)c12 RFQPHWCAHNTCDX-UHFFFAOYSA-N 0.000 description 1
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 맥문동 추출물; 및 백자인, 만형자, 향부자, 감국, 상백피, 천궁, 백지, 세신, 측백엽, 한련초, 생강 및 인삼으로 이루어진 군에서 선택되는 어느 하나 이상의 천연 추출물;을 유효성분으로 함유하는 조성물에 관한 것이다.The present invention is maekmundong extract; And white jain, manhyeongja, hyangbuja, chrysanthemum, sangbaekpi, cheongung, baekji, sesin, chrysanthemum, orchid, ginger and ginseng; it relates to a composition containing as an active ingredient any one or more natural extracts selected from the group consisting of.
Description
본 발명은 맥문동 추출물 및 천연 추출물을 유효성분으로 함유하는 조성물에 관한 것이다.The present invention relates to a composition comprising a maekmundong extract and a natural extract as active ingredients.
탈모의 원인에 관하여서는 모근, 피지선 등의 기관에서 남성 호르몬의 작용설, 모낭 (Hair follicle)의 혈류량 저하, 비듬균 번식이나 피지 분비 과다에 의한 두피 이상설, 유전적 요인 그리고 노화 등이 거론되어 왔다. 그러나 아직까지 탈모에 대한 명확한 원인은 규명되고 있지 않고, 최근 들어 오히려 탈모증으로 고민하는 사람이 점점 늘고 있으며 그 연령층도 낮아지고 있는 실정이다. Regarding the cause of hair loss, the theory of the action of male hormones in organs such as the hair root and sebaceous glands, the decrease in blood flow in the hair follicle, the scalp abnormality due to dandruff growth or excessive sebum secretion, genetic factors, and aging have been discussed. However, the clear cause of hair loss has not yet been identified, and recently, more and more people are suffering from alopecia, and the age group is also decreasing.
인체의 모발은 약 130만개 이상, 두발은 10만개 이상이며 이들 모발은 성장기(anagen), 퇴화기(catagen), 휴지기(telogen)의 3단계 주기를 거치며 각 모발은 독립적인 주기로 활동하며 진행된다. 탈모는 머리카락이나 털이 어떤 원인에 의하여 정상보다 적거나 없는 상태를 의미하며, 크게 모발이 휴지기 상태에서 빠지는 일반적인 탈모 현상(휴지기 탈모, telogen effluvium)과 비정상적인 탈모 현상인 생장기 탈모 현상(anagen effluvium)으로 구별할 수 있는 데, 후자를 일반적으로 탈모라 일컫는다. 탈모(또는 탈모 질환)는 형태, 증상 또는 원인 등에 따라, 원형 탈모증(Alopecia Areata), 유전성 안드로겐 탈모증(Androgenetic Alopecia), 휴지기 탈모증(Telogen Effluvium), 외상성, 발모벽(Trichoti lomania), 압박성(Pressure Alopecia)등의 생장기 탈모증, 비강성, 매독성(Alopecia syphlltiac), 지루 탈모증(Alopecia seborrhecia), 증후성, 반흔성, 선천성 탈모증 등으로 분류되고 있다.The human body has more than 1.3 million hairs and more than 100,000 hairs. These hairs go through three phases of anagen, catagen, and telogen, and each hair operates in an independent cycle. Hair loss refers to a state in which there is less or no hair than normal due to some cause, and it is largely divided into a general hair loss phenomenon (telogen effluvium), in which hair falls out in the resting state (telogen effluvium), and an abnormal hair loss phenomenon, anagen effluvium. It is possible, but the latter is commonly referred to as hair loss. Hair loss (or hair loss disease) is, depending on the type, symptom, or cause, alopecia Areata, Androgenetic Alopecia, Telogen Effluvium, Traumatic, Trichoti lomania, Pressure Alopecia), etc., are classified into anaphylactic, syphilis (Alopecia syphlltiac), seborrheic alopecia (Alopecia seborrhecia), symptomatic, scarring, and congenital alopecia.
종래의 탈모증 치료방법으로는, 호르몬설과 관련하여 여성 호르몬을 주재로 한 제제가 있으나 효과뿐 아니라 피부 염증 발생, 호르몬 투여에 의한 부작용 발생 등의 보고가 있어 현재는 사용이 중단되고 있다. 발모제로서 미국 업존사의 미녹시딜(minoxidil), 이태리 크리노스(Crinos, Co.)사의 트리코사카라이드 (trichosaccharide)등을 주성분으로 하는 제제가 사용되고 있으나 뚜렷한 효과의 부재 및 부작용 문제가 대두되고 있다. 또한 머크사에서 개발한 피나스테라이드(finasteride)는 모낭에서 남성호르몬 테스토스테론 대사에 작용하는 효소인 5-α-리덕테이즈(5-α-reductase)의 활성을 억제시키는 물질로 알려져 있으나 우울증을 유발할 수 있으며 이 또한 장기간의 치료가 필요하다는 문제점을 안고 있다. 이 외에도 크레시나와 로게인이 있지만, 탈모 질환이 완전히 진행되기 전인 정상 두피에 모근이 살아있는 경우에만 사용된다. 이처럼 종래의 여러 종류의 발모제는 일반적으로 두피의 혈행 촉진과 모근의 영양공급을 목적으로 하여 모발의 성장에 도움을 주도록 하는 방법이 시도되었으나 이 역시 독성과 부작용이 심하고 그 효과 또한 미흡한 것이 현재 실정이다.As a conventional method for treating alopecia, there are preparations mainly based on female hormones in relation to hormone theory, but there are reports of not only effects, but also skin inflammation, side effects caused by hormone administration, etc., so their use is currently discontinued. As a hair growth agent, preparations containing minoxidil of Upzon of the United States and trichosaccharide of Trichosaccharide of Crinos Co. of Italy are used as main ingredients, but the absence of a clear effect and the problem of side effects are emerging. In addition, finasteride developed by Merck is known to inhibit the activity of 5-α-reductase, an enzyme that acts on the male hormone testosterone metabolism in hair follicles, but it can cause depression. This also has the problem of requiring long-term treatment. In addition to these, there are Crescina and Rogaine, but they are used only when hair roots are alive on the normal scalp before the hair loss disease has completely progressed. As such, various types of conventional hair regenerative agents have been attempted to help hair growth for the purpose of promoting blood circulation to the scalp and supplying nutrients to the hair roots, but these also have severe toxicity and side effects, and the effect is insufficient. .
한편, 맥문동은 백합과의 식물로 탈모 개선에 대한 일부 효능이 알려져 있기는 하나, 탈모에 가시적인 효능을 나타낼 수 있는 조성에 아직 구체적으로 알려진 바가 없으며, 탈모 개선 이외에 다른 효능을 나타낼 수 있는 조성 역시 아직 구체적으로 알려진 바가 없다.On the other hand, although maekmundong is a plant of the Liliaceae family, some efficacy for hair loss improvement is known, but a composition that can show a visible effect on hair loss has not yet been specifically known, and a composition that can exhibit other effects other than hair loss improvement is also Nothing concrete is known yet.
본 발명은 종래의 맥문동 추출물을 함유하는 조성물보다도 탈모방지 및 두피개선 효과가 우수하고, 항비듬 효과가 우수하며, 항염증 효과가 우수하고, 항균 효과가 우수하며, 피지 억제 효과가 우수한 조성물을 제공하고자 한다.The present invention provides a composition that is superior in preventing hair loss and improving scalp, has excellent anti-dandruff effect, has excellent anti-inflammatory effect, has excellent antibacterial effect, and has excellent sebum suppression effect, than the conventional composition containing the extract of maekmundong. want to
본 발명은 맥문동 추출물; 및 백자인, 만형자, 향부자, 감국, 상백피, 천궁, 백지, 세신, 측백엽, 한련초, 생강 및 인삼으로 이루어진 군에서 선택되는 어느 하나 이상의 천연 추출물;을 유효성분으로 함유하는 조성물을 제공한다.The present invention is maekmundong extract; And white jain, manhyeongja, hyangbuja, chrysanthemum, sangbaekpi, cheongung, baekji, sesin, chrysanthemum, orchid, ginger and ginseng, any one or more natural extracts selected from the group consisting of; provides a composition containing as an active ingredient.
본 발명에 따른 화장료 조성물은 맥문동 추출물과 함께 종래에 알려지지 않은 특유한 구성의 천연 추출물을 함유함으로써, 탈모방지 및 두피개선 효과가 우수하고, 항비듬 효과가 우수하며, 항염증 효과가 우수하고, 항균 효과가 우수하며, 피지 억제 효과가 우수하다.The cosmetic composition according to the present invention contains a natural extract of a previously unknown unique composition along with the extract of maekmundong, and thus has excellent hair loss prevention and scalp improvement effects, excellent anti-dandruff effect, excellent anti-inflammatory effect, and antibacterial effect. It has excellent sebum suppression effect.
이하, 본 발명에 따른 조성물에 대하여 자세하게 설명한다.Hereinafter, the composition according to the present invention will be described in detail.
맥문동은 백합과의 식물로 학명은 Ophiopogon Japonicus 또는 Liriope platyphylla 이다. 포함하고 있는 성분으로는 오피오포고닌(Ophiopogonon) A-E, 스피카토시드(Spicatoside) A-B 등 스테로이달 사포닌, 오피오포나논(Ophioponanone) C-F, 오피오포고논(Ophiopogonone) C 등 플라보노이드 가 알려져 있으며 수집종과 재배방법에 따라 그 성분의 차이가 나타난다고 보고되고 있다. Maekmundong is a plant in the family Liliaceae and its scientific name is Ophiopogon. Japonicus or Liriope platyphylla . Steroidal saponins such as Ophiopogonon AE, Spicatoside AB, and flavonoids such as Ophioponanone CF and Ophiopogonone C are known as ingredients. It has been reported that there are differences in the composition depending on the method.
감국은 국화과의 식물로 학명은 Chrysanthemum indicum이다. 포함하고 있는 성분으로는 리나린(Linarin), 퀘르세틴(Quercetine) 등 플라보노이드 화합물과 시나린(Cynarin) 등 페놀화합물이 알려져 있다.Chrysanthemum is a plant in the Asteraceae family and its scientific name is Chrysanthemum indicum . Flavonoid compounds such as Linarin and Quercetine and phenolic compounds such as Cynarin are known as ingredients.
만형자는 마편초과의 식물로 학명은 Vitex trifolia 또는 Vitex rotundifolia이다. 포함하고 있는 성분으로는 비텍스칼핀(Vitexcarpin), 아르테메틴(Artemetin), 헤스페리딘(Hesperidin) 등 플라보노이드가 알려져 있다.Mangyeongja is a plant in the Verbena family and the scientific name is Vitex. trifolia or Vitex rotundifolia . Flavonoids such as Vitexcarpin, Artemetin, and Hesperidin are known as ingredients.
인삼은 두릅나무과의 식물로 학명은 Panax ginseng이다. 포함하고 있는 성분으로는 진세노사이드(Ginsenoside Rb1-2) 등 사포닌이 알려져 있다.Ginseng is a plant of the Araliaceae family, and its scientific name is This is Panax ginseng . Saponins such as ginsenoside (Ginsenoside Rb1-2) are known as ingredients.
한련초는 국화과의 식물로 학명은 Eclipta prostrata이다. 포함하고 있는 성분으로는 에크랄바사포닌(Eclalbasaponin) Ⅰ-Ⅳ 등 사포닌, 웨델로락톤(Wedelolactone) 등 플라보노이드가 알려져 있다.Orchid is a plant in the Asteraceae family and its scientific name is Eclipta. It is prostrata . Saponins such as Eclalbasaponin I-IV, and flavonoids such as Wedelolactone are known as ingredients.
측백엽은 측백나무과의 식물로 Thuja orientalis의 잎으로 항균효능과 항염효능이 뛰어나다고 알려져 있다. 향부자는 방동사니과의 식물로 학명은 Cyperus rotundus으로, 전통의약서에서는 통증을 풀어주며 경맥을 돕는 효능이 있다고 설명하고 있다.Arborvitae is a plant in the arboraceae family, Thuja Orientalis leaves are known to have excellent antibacterial and anti-inflammatory effects. Hyangbuja is a plant belonging to the genus cyperaceae and its scientific name is Cyperus rotundus , and traditional medicines describe that it has the effect of relieving pain and helping the meridians.
백자인은 측백나무과 식물의 잎으로로 그 학명은 Thuja orientalis이다.White jain is the leaf of the Arboraceae plant, its scientific name is Thuja. orientalis .
상백피는 뽕나무과의 식물로 학명은 Morus alba이다. 포함하고 있는 성분으로는 Mrusin, Kuwanon E-R 등 플라보노이드가 알려져 있다.The sagebrush is a plant of the Morus family and its scientific name is Morus. It is alba . Flavonoids such as Mrusin and Kuwanon ER are known as ingredients.
생강은 생강과의 식물로 학명은 Zingiber officinale이다. 포함하고 있는 성분으로는 진저론(gingerone)과 쇼가올(shoagaol) 등 페놀화합물이 알려져 있다.Ginger is a plant in the ginger family and its scientific name is Zingiber. It is officinale . Known ingredients include phenolic compounds such as gingerone and shoagaol.
천궁은 미나리과의 식물로 학명은 Cnidium officinale이다..Cnidaria is a plant of the buttercup family and its scientific name is Cnidium. It is officinale .
본 발명의 일 실시상태에 있어서, 상기 맥문동 추출물의 함량은 조성물 전체 중량에 대하여, 0.01 중량% 내지 10 중량%이다. 그 함량이 0.01중량% 미만이면 탈모방지 및 두피개선 효과가 거의 나타나지 않고, 10중량%를 초과하면 제형에 영향을 미칠 수 있다.In an exemplary embodiment of the present invention, the content of the maekmundong extract is 0.01 wt% to 10 wt%, based on the total weight of the composition. If the content is less than 0.01% by weight, hair loss prevention and scalp improvement effects hardly appear, and if it exceeds 10% by weight, the formulation may be affected.
본 발명의 일 실시상태에 있어서, 상기 천연 추출물의 함량은 조성물 전체 중량에 대하여, 0.01 중량% 내지 10 중량%이다.In one embodiment of the present invention, the content of the natural extract is 0.01 wt% to 10 wt%, based on the total weight of the composition.
본 발명의 일 실시상태에 있어서, 상기 조성물은 맥문동; 및 백자인, 만형자, 향부자, 감국, 상백피, 천궁, 백지, 세신, 측백엽, 한련초, 생강 및 인삼으로 이루어진 군에서 선택되는 어느 하나 이상에 물을 첨가하여 95℃ 내지 100℃의 온도로 열수추출하여 수득한 추출물을 함유한다.In one embodiment of the present invention, the composition is maekmundong; And by adding water to any one or more selected from the group consisting of white jain, manhyeongja, hyangbuja, chrysanthemum, sangbaekpi, cheongung, white paper, sesin, chrysanthemum, ginseng, and hot water extraction at a temperature of 95°C to 100°C. The obtained extract is contained.
본 발명의 일 실시상태에 있어서, 상기 조성물은 맥문동; 및 백자인, 만형자, 향부자, 감국, 상백피, 천궁, 백지, 세신, 측백엽, 한련초, 생강 및 인삼으로 이루어진 군에서 선택되는 어느 하나 이상에 물을 첨가하여 20℃ 내지 25℃의 온도로 저온추출하여 수득한 추출물을 함유한다.In one embodiment of the present invention, the composition is maekmundong; And by adding water to any one or more selected from the group consisting of white ginseng, manhyeongja, hyangbuja, chrysanthemum, sangbaekpi, cheongung, white paper, sesin, chrysanthemum, orchid, ginger, and ginseng at a temperature of 20 ° C. to 25 ° C. by low temperature extraction. The obtained extract is contained.
본 발명에 따른 조성물에 함유되는 상기 추출물들은 식물체로부터 유효성분을 추출하기 위하여 통상적으로 사용되는 방법에 의해 천연으로부터 추출 및 분리하여 수득한 것을 사용할 수 있으며, 본 발명에서 정의된 '추출물'은 적절한 용매를 이용하여 추출한 것이며 열수추출물, 극성용매 가용추출물 또는 비극성용매 가용 추출물을 모두 포함할 수 있다. As the extracts contained in the composition according to the present invention, those obtained by extraction and separation from nature by a method commonly used to extract active ingredients from plants may be used, and 'extract' as defined in the present invention is an appropriate solvent. It is extracted using a hot water extract, polar solvent soluble extract or non-polar solvent soluble extract may all include.
추출물을 제조하기 위한 적절한 용매로는 당업계에서 허용되는 용매라면 어느 것을 사용해도 무방하며, 물 또는 유기용매를 사용할 수 있다. 예를 들어, 정제수, 메탄올(methanol), 에탄올(ethanol), 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol) 등을 포함하는 탄소수 1 내지 4의 알코올, 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌클로라이드(methylene chloride), 헥산(hexane) 및 시클로헥산(cyclohexane) 등의 각종 용매를 단독으로 혹은 혼합하여 사용할 수 있으나, 이에 제한되지는 않는다.As a suitable solvent for preparing the extract, any solvent acceptable in the art may be used, and water or an organic solvent may be used. For example, purified water, methanol (methanol), ethanol (ethanol), propanol (propanol), isopropanol (isopropanol), alcohols having 1 to 4 carbon atoms including butanol (butanol), acetone (acetone), ether (ether) , benzene (benzene), chloroform (chloroform), ethyl acetate (ethyl acetate), methylene chloride (methylene chloride), hexane (hexane) and various solvents such as cyclohexane (cyclohexane) can be used alone or in combination, but Not limited.
추출 방법으로는 열수추출법, 냉침추출법, 환류냉각추출법, 용매추출법, 수증기증류법, 초음파추출법, 용출법, 압착법 등의 방법 중 어느 하나 이상의 방법을 선택하여 사용할 수 있다. 또한, 목적하는 추출물은 추가로 통상의 분획 공정을 수행할 수도 있으며, 통상의 정제 방법을 이용하여 정제될 수도 있다. 본 발명의 추출물의 제조방법은 종래 공지되어 있는 방법도 이용될 수 있다.As the extraction method, any one or more methods such as hot water extraction method, cold extraction method, reflux cooling extraction method, solvent extraction method, steam distillation method, ultrasonic extraction method, elution method, compression method, etc. can be selected and used. In addition, the desired extract may be further subjected to a conventional fractionation process, and may be purified using a conventional purification method. The method for preparing the extract of the present invention may also be used in a conventionally known method.
예를 들면, 본 발명의 조성물에 포함되는 추출물은 상기한 열수 추출 또는 용매 추출법으로 추출된 1차 추출물을, 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조할 수 있다. 또한 상기 1차 추출물을 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 박층 크로마토그래피(thin layer chromatography), 고성능 액체 크로마토그래피(high performance liquid chromatography) 등과 같은 다양한 크로마토그래피를 이용하여 추가로 정제된 분획을 얻을 수도 있다. For example, the extract included in the composition of the present invention may be prepared in a powder state by an additional process such as distillation under reduced pressure and freeze-drying or spray-drying the primary extract extracted by the hot water extraction or solvent extraction method described above. In addition, the first extract was further purified using various chromatography methods such as silica gel column chromatography, thin layer chromatography, and high performance liquid chromatography. you may get
따라서, 본 발명에 있어서 추출물은 추출, 분획 또는 정제의 각 단계에서 얻어지는 모든 추출액, 분획 및 정제물, 그들의 희석액, 농축액 또는 건조물을 모두 포함하는 개념이며, 추출물은 각 생약재의 별도의 추출물을 혼합하여 이용할 수도 있고, 생약재를 혼합한 후 한꺼번에 추출하여 제조된 것을 사용할 수도 있다. 또한 본 발명에 의한 추출물은 1,3-부틸렌글라이콜에 녹여 조성물에 배합할 수 있다.Therefore, in the present invention, the extract is a concept including all extracts, fractions and purified substances obtained in each step of extraction, fractionation or purification, their dilutions, concentrates, or dried substances, and the extract is obtained by mixing separate extracts of each herbal medicine. It may be used, or one prepared by mixing herbal materials and extracting them all at once may be used. In addition, the extract according to the present invention can be dissolved in 1,3-butylene glycol and blended into the composition.
본 발명의 일 실시상태에 있어서, 상기 조성물은 상기 열수추출하여 수득한 추출물 또는 상기 저온추출하여 수득한 추출물에 에틸아세테이트를 첨가하고 에틸아세테이트 분획하여 상층으로 분리되는 에틸아세테이트 분획물을 함유한다.
본 발명의 일 실시상태에 있어서, 상기 조성물은 상기 에틸아세테이트 분획으로 분리되지 않은 하층에 부탄올을 첨가하여 상층으로 분리되는 부탄올 분획물을 함유한다.In an exemplary embodiment of the present invention, the composition contains an ethyl acetate fraction separated into an upper layer by adding ethyl acetate to the extract obtained by the hot water extraction or the extract obtained by the low temperature extraction, followed by ethyl acetate fractionation.
In one embodiment of the present invention, the composition contains a butanol fraction separated into an upper layer by adding butanol to the lower layer that is not separated into the ethyl acetate fraction.
삭제delete
본 발명의 일 실시상태에 있어서, 상기 조성물은 상기 열수추출하여 수득한 추출물 또는 상기 저온추출하여 수득한 추출물에 에탄올을 첨가하여 수득한 추출물을 함유한다.In one embodiment of the present invention, the composition contains the extract obtained by adding ethanol to the extract obtained by the hot water extraction or the extract obtained by the low temperature extraction.
본 발명에 따른 화장료 조성물은 모유두세포 보호 효과가 우수한 상기 조성물은 탈모방지 또는 두피개선용이다.The cosmetic composition according to the present invention is excellent for protecting dermal papilla cells, and the composition is for preventing hair loss or improving the scalp.
또한, 본 발명에 따른 화장료 조성물은 자유라디칼 억제 및 활성 산소 억제 효과가 우수한 항산화용이다.In addition, the cosmetic composition according to the present invention is for antioxidants with excellent free radical suppression and active oxygen suppression effects.
또한, 본 발명에 따른 화장료 조성물은 상기 조성물은 비듬 원인균에 대한 억제 효과가 우수한 항비듬용이다.In addition, the cosmetic composition according to the present invention is for anti-dandruff excellent in the inhibitory effect on the dandruff causative bacteria.
또한, 본 발명에 따른 화장료 조성물은 상기 조성물은 세균에 대한 억제 효과가 우수한 항균용이다.In addition, the cosmetic composition according to the present invention is an antibacterial composition having an excellent inhibitory effect on bacteria.
또한, 본 발명에 따른 화장료 조성물은 상기 조성물은 피지 생성을 억제하는 효과가 우수한 피지 억제용이다.In addition, the cosmetic composition according to the present invention is for the suppression of sebum having an excellent effect of inhibiting the production of sebum.
본 발명에 일 실시상태에 있어서, 상기 조성물은 화장료 조성물이다. 상기 조성물은 화장료로서 피부에 외용이 허용되는 범위 내에서 다른 성분이 더 첨가될 수 있다.In one embodiment of the present invention, the composition is a cosmetic composition. In the composition, other ingredients may be further added within a range that is acceptable for external application to the skin as a cosmetic.
본 발명에 일 실시상태에 있어서, 상기 조성물은 식품 조성물이다. 상기 조성물은 인간이 섭취가 허용되는 성분의 범위 내에서 다른 성분이 더 첨가될 수 있다.In one embodiment of the present invention, the composition is a food composition. In the composition, other ingredients may be further added within the range of ingredients acceptable for human ingestion.
또한, 본 발명에 따른 화장료 조성물은 자유라디칼 억제 및 활성 산소 억제 효과가 우수한 항산화용인 화장료 조성물이다.In addition, the cosmetic composition according to the present invention is a cosmetic composition for antioxidants having excellent free radical suppression and active oxygen suppression effects.
또한, 본 발명에 따른 화장료 조성물은 엘라스테이즈 억제 효과가 우수하고, 콜라겐 합성 활성 효과가 우수하며, MMP-1 억제 효과가 우수한 피부 주름 개선 또는 예방용인 화장료 조성물이다.In addition, the cosmetic composition according to the present invention is a cosmetic composition for improving or preventing skin wrinkles having excellent elastase inhibitory effect, excellent collagen synthesis activity effect, and excellent MMP-1 inhibitory effect.
또한, 본 발명에 따른 화장료 조성물은 NO 억제가 우수한 항염증용인 화장료 조성물이다.In addition, the cosmetic composition according to the present invention is an anti-inflammatory cosmetic composition with excellent NO inhibition.
또한, 본 발명에 따른 화장료 조성물은 피부 보습 효과, 항산화 효과, 피부 주름 개선 또는 예방 효과 및 항염증 효과가 우수한 항노화용인 화장료 조성물이다.In addition, the cosmetic composition according to the present invention is an anti-aging cosmetic composition having excellent skin moisturizing effect, antioxidant effect, skin wrinkle improvement or prevention effect, and anti-inflammatory effect.
이하, 실시예를 들어 본 발명을 보다 자세하게 설명한다. 그러나 이러한 실시예들은 본 발명을 구체적으로 설명하려는 것일 뿐, 이러한 실시예에 의하여 본 발명의 권리범위가 제한되는 것은 아니다.Hereinafter, the present invention will be described in more detail by way of Examples. However, these examples are only intended to describe the present invention in detail, and the scope of the present invention is not limited by these examples.
<실시예 1> 열수 추출물의 제조
맥문동, 백자인, 만형자, 향부자, 감국, 상백피, 천궁, 백지, 세신, 측백엽, 한련초, 생강 및 인삼을 각 100g을 취하여 정제수 1L 내지 2L를 첨가한 후, 95℃ 내지 100℃의 온도에서 환류장치 하에서 10~15시간동안 끓이면서 추출하였다. 추출완료 후 원물을 제거한 추출액을 회전식감암농축기로 농축하고 동결건조하여 고체상태의 열수 추출물을 수득하였다.
<실시예 2> 저온 추출물의 제조
맥문동, 백자인, 만형자, 향부자, 감국, 상백피, 천궁, 백지, 세신, 측백엽, 한련초, 생강 및 인삼을 각 100g을 취하여 정제수 1L 내지 2L를 첨가한 후 20℃ 내지 25℃의 상온에서 1주 내지 3주 동안 유지하여 유효성분을 용출하였다. 용출완료 후 원물을 제거한 용출액을 회전식감암농축기로 농축하고 동결건조하여 고체상태의 저온 추출물을 수득하였다.
<실시예 3> 에틸아세테이트 분획물의 제조
상기 실시예 1의 열수 추출물에 정제수 1L 내지 2L를 가한 뒤 생기는 침전물을 여과하여 제거하고, 여기에 에틸아세테이트를 첨가하여 잘 섞은 다음 방치하여 상층과 하층으로 분리시킨 뒤 상층을 수득한 후, 회전식 감압농축기로 농축하고 동결건조하여 고체상태의 에틸아세테이트 분획물을 수득하였다.
<실시예 4> 부탄올 분획물의 제조
상기 실시예 3에서 에틸아세테이트의 첨가로 분리된 하층에 부탄올 1L 내지 2L을 가하여 잘 섞은 다음 방치하여 상층과 하층으로 분리시킨 뒤 상층을 수득한 후, 회전식 감압농축기로 농축하고 동결건조하여 고체상태의 부탄올 분획물을 수득하였다.
<실시예 5> 다당 분획물의 제조 <Example 1> Preparation of hot water extract
100 g each of Maekmundong, Baekjain, Manhyeongja, Hyangbuja, Gamguk, Sangbaekpi, Cheongung, Baekji, Sesin, Arachnid leaves, Hanryeoncho, Ginger and Ginseng were added to 1L to 2L of purified water, and then refluxed at a temperature of 95°C to 100°C. It was extracted while boiling for 10 to 15 hours under After completion of the extraction, the extract from which the raw material was removed was concentrated with a rotary permeate concentrator and freeze-dried to obtain a solid hot water extract.
<Example 2> Preparation of low-temperature extract
100 g each of maekmundong, white jain, manhyeongja, hyangbuja, gamguk, sangbaekpi, cheongung, baekji, sesin, chrysanthemum, chrysanthemum, ginger and ginseng were added to 1L to 2L of purified water, and then from 20℃ to 25℃ at room temperature for 1 week to It was maintained for 3 weeks to elute the active ingredient. After completion of elution, the eluate from which the raw material was removed was concentrated with a rotary permeate concentrator and freeze-dried to obtain a solid low-temperature extract.
<Example 3> Preparation of ethyl acetate fraction
After adding 1 L to 2 L of purified water to the hot water extract of Example 1, the precipitate formed is filtered off, and ethyl acetate is added thereto, mixed well, left to stand to separate into an upper layer and a lower layer, and after obtaining the upper layer, the rotary pressure reduction Concentrated with a concentrator and freeze-dried to obtain a solid ethyl acetate fraction.
<Example 4> Preparation of butanol fraction
1L to 2L of butanol was added to the lower layer separated by the addition of ethyl acetate in Example 3, mixed well and left to separate into upper and lower layers to obtain an upper layer, concentrated with a rotary vacuum concentrator and freeze-dried to obtain a solid state A butanol fraction was obtained.
<Example 5> Preparation of polysaccharide fraction
상기 실시예 1의 열수 추출물을 회전식감암농축기로 농축하여 수득한 농축액에 에탄올을 가하여 생기는 침전물을 진공건조하여 고체상태의 다당 분획물을 수득하였다.The hot water extract of Example 1 was concentrated with a rotary tannery concentrator, and the precipitate formed by adding ethanol to the concentrated solution was vacuum-dried to obtain a solid polysaccharide fraction.
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
<< 실험예Experimental example 1> 항산화 효능 측정 1> Measurement of antioxidant efficacy
항산화 효과를 확인하기 위하여 자유라디칼소거시험 및 활성산소소거시험을 실시하였다. 시험에 사용한 시료는 상기 실시예 1 내지 5에서 수득한 시료이며, 항산화효과를 비교하기 위하여 항산화효과가 뛰어난 아스코르브산(L-ascorbic acid)을 양성 대조군으로 이용하였다.In order to confirm the antioxidant effect, free radical scavenging test and active oxygen scavenging test were performed. The samples used for the test were samples obtained in Examples 1 to 5, and ascorbic acid having excellent antioxidant effect was used as a positive control in order to compare the antioxidant effect.
자유라디칼 소거시험은 안정한 DPPH의 흡광도가 540nm에서 최대 흡광도를 나타는 것을 이용하고, 자유라디칼인 DPPH가 시료에 의해 소거되어 보라색에서 투명한 색이 될수록, 자유라디칼 소거율이 증가할수록 상기 540nm파장 에서 흡광도가 줄어들게 됨을 응용하여 검정시험방법에 의해 진행하였다.The free radical scavenging test uses the stable absorbance of DPPH that shows the maximum absorbance at 540 nm, and as the free radical DPPH is cleared by the sample and becomes a transparent color from purple, as the free radical scavenging rate increases, the absorbance at the 540 nm wavelength It was carried out by the test method by applying the decrease in .
0.1mM DPPH(2,2-diphenyl-1-picryl-hydrazyl radical, Sigma) 용액 1㎖에 상기의 실시예 1 내지 5에서 수득한 시료를 메탄올에 적당한 농도로 희석하여 1㎖를 혼합하고, 37℃에서 15분간 방치한 후, 마이크로플레이트 리더(microplate reader, UVT-06685, Thermo max, 미국)를 이용하여 540nm 파장에서 흡광도를 측정하였다. In 1 ml of 0.1 mM DPPH (2,2-diphenyl-1-picryl-hydrazyl radical, Sigma) solution, the samples obtained in Examples 1 to 5 were diluted to an appropriate concentration in methanol, 1 ml was mixed, and the mixture was mixed at 37 ° C. After leaving for 15 minutes in a microplate reader (microplate reader, UVT-06685, Thermo max, USA) was used to measure the absorbance at a wavelength of 540nm.
상기 자유라디칼 소거시험에서 대조군은 DPPH 1㎖과 메탄올 1㎖를 넣어 같은 방법으로 측정하였으며, 메탄올 1㎖과 시료 1㎖를 넣어 시료와 대조군에 대한 각각의 색 보정값을 얻었다. 하기 수학식 1을 이용하여 자유라디칼소거율을 계산하였으며, IC50은 자유라디칼을 50% 소거하기 위해 소요되는 시료의 농도이고, 값이 작을수록 항산화활성이 높음을 의미한다.In the free radical scavenging test, the control was measured in the same manner by adding 1 ml of DPPH and 1 ml of methanol, and 1 ml of methanol and 1 ml of the sample were added to obtain color correction values for the sample and the control, respectively. The free radical scavenging rate was calculated using Equation 1 below, and IC 50 is the concentration of the sample required to remove 50% of free radicals, and the smaller the value, the higher the antioxidant activity.
[수학식 1][Equation 1]
자유라디칼 소거율(%)= 100-((시료의 흡광도/대조군의 흡광도)×100)Free radical scavenging rate (%) = 100-((absorbance of sample / absorbance of control) × 100)
활성산소 소거시험은 잔틴/잔틴옥시데이즈(xanthine/xanthine oxidase)의 효소반응에 의한 활성산소 발생을 이용하여 활성산소에 의한 니트로블루 테트라졸리움(nitroblue tetrazolium, NBT)의 산화를 이용한 흡광도 변화를 측정함으로써 활성 산소의 소거능을 알 수 있다.The active oxygen scavenging test is by measuring the change in absorbance using the oxidation of nitroblue tetrazolium (NBT) by active oxygen using the generation of active oxygen by the enzymatic reaction of xanthine / xanthine oxidase. It can be seen that the scavenging ability of active oxygen.
탄산나트륨(Na2CO3) 2.4㎖, 잔틴(xanthine) 0.1㎖, 에틸렌디아민테트라아세트산 (ethylenediamine tetraacetic acid, EDTA) 0.1㎖, 소혈청알부민(bovine serum albumin, BSA, Sigma) 0.1㎖, NBT 0.1㎖ 및 시료 0.1㎖을 넣고 볼텍서 믹서(vortex mixer, Type 37600 Mixer, USA)를 이용하여 voltexing하고 25℃에서 10분간 방치한 후, 잔틴산화효소(xanthine oxidase) 0.1㎖을 넣고 25℃에서 20분간 반응, 6mM CuCl2를 넣어 반응을 정지, 마이크로플레이트 리더를 이용하여 540㎚파장에서 흡광도를 측정하였다Sodium carbonate (Na 2 CO 3 ) 2.4 ml, xanthine 0.1 ml, ethylenediamine tetraacetic acid (EDTA) 0.1 ml, bovine serum albumin (BSA, Sigma) 0.1 ml, NBT 0.1 ml and Put 0.1 ml of the sample, voltex it using a vortex mixer (Type 37600 Mixer, USA), and leave it at 25 ° C for 10 minutes, then add 0.1 ml of xanthine oxidase and react at 25 ° C for 20 minutes, 6mM CuCl 2 was added to stop the reaction, and absorbance was measured at a wavelength of 540 nm using a microplate reader.
상기 활성산소소거활성시험에서의 대조군은 시료용액 대신 3차 증류수를 넣어 같은 방법으로 측정하였으며, 잔틴화효소 용액 대신 3차 증류수를 넣어 추출 시료와 대조군에 대한 각각의 색 보정값을 얻는 것으로 설정하였다.The control group in the active oxygen scavenging activity test was measured in the same way by adding tertiary distilled water instead of the sample solution, and adding tertiary distilled water instead of the xanthylase solution to obtain each color correction value for the extracted sample and the control was set. .
하기 수학식 2을 이용하여 활성산소소거율을 계산하였으며, IC50은 활성산소를 50% 소거하기 위해 소요되는 시료의 농도이고, 값이 작을수록 항산화활성이 높음을 의미한다.The active oxygen scavenging rate was calculated using Equation 2 below, and IC 50 is the concentration of the sample required to remove 50% of active oxygen, and the smaller the value, the higher the antioxidant activity.
[수학식 2][Equation 2]
활성산소 소거율(%)= 100-((시료의 흡광도/대조군의 흡광도)×100)Reactive oxygen scavenging rate (%) = 100-((absorbance of sample / absorbance of control group) × 100)
상기 실시예 1 내지 5의 시료로 자유라디칼 소거율 및 활성산소 소거율을 측정하였으며, 대조군으로서 L-아스코르브산을 사용하여 그 측정 결과를 하기 표 1과 같이 나타내었다.The free radical scavenging rate and active oxygen scavenging rate were measured with the samples of Examples 1 to 5, and the measurement results are shown in Table 1 below using L-ascorbic acid as a control.
상기 표 1에서와 같이, 본 발명에 따른 실시예 1 내지 5는 열수추출물과 저온추출물의 항산화 효능 비교한 결과 저온추출물의 항산화 효능이 열수추출물보다 뛰어남을 확인하였으며, 분획물의 항산화 효능은 부탄올 분획물, 다당체 분획물, 에틸아세테이트 분획물 순서임을 확인하였다.As shown in Table 1, Examples 1 to 5 according to the present invention compared the antioxidant efficacy of the hot-water extract and the low-temperature extract, it was confirmed that the antioxidant efficacy of the low-temperature extract was superior to that of the hot-water extract, and the antioxidant efficacy of the fraction was the butanol fraction, It was confirmed that the polysaccharide fraction and the ethyl acetate fraction were in order.
<< 실험예Experimental example 2> 2> 모유두세포dermal papilla cells 보호효과 측정 Protection effectiveness measurement
모유두세포는 모낭의 기저부에 존재하는 세포로, 모낭을 구성하는 세포들에게 산소와 영양을 공급하여 모발의 성장과 모낭 주기 조절을 담당한다. 따라서 모유두세포의 증식이 촉진되면 모발이 건강해지고 모발 성장이 촉진되며 탈모를 막을 수 있다. 모발의 성장은 모유두(dermal papilla)를 둘러싸고 있는 상피세포(epithelialcell)가 분열하여 모간(hair shaft)을 만들면서 진행되기 때문에 모유두세포는 상피세포의 분열을 조절하는 중요한 역할을 한다. 또한 남성형 탈모증에서 남성호르몬이 모낭에 작용하는 부위 역시 모유두로서 모유두세포는 발모에 있어 매우 중요한 역할을 하고 있다. The dermal papilla cells exist at the base of the hair follicle and are responsible for hair growth and hair follicle cycle regulation by supplying oxygen and nutrients to the cells constituting the hair follicle. Therefore, when the proliferation of dermal papilla cells is promoted, hair becomes healthy, hair growth is promoted, and hair loss can be prevented. Because hair growth proceeds as the epithelial cells surrounding the dermal papilla divide to form a hair shaft, the dermal papilla cells play an important role in regulating the division of epithelial cells. Also, in androgenetic alopecia, the site where male hormones act on hair follicles is also the dermal papilla, and dermal papilla cells play a very important role in hair growth.
모발은 지속적인 생장을 위해 왕성한 세포 분열이 필요하며 이에 따라 산화스트레스가 심한 기관이다. 따라서, 산화스트레스로부터 모발 모유두세포를 보호할 수 있는 실시예 1 내지 5의 시료는 탈모방지에 효과적으로 작용할 것으로 예상하여 각 시료가 모발 모유듀세포를 산화 스트레스로부터 보호할 수 있는지 평가하였다. Hair is an organ with severe oxidative stress as it requires vigorous cell division for continuous growth. Therefore, the samples of Examples 1 to 5, which can protect the hair dermal papilla cells from oxidative stress, were expected to act effectively in preventing hair loss, and it was evaluated whether each sample could protect the hair dermal papilla cells from oxidative stress.
모유두세포를 96 well에 5,000개 접종하여 24 시간 배양 후 소태아혈청이 없는 DMEM 배지에서 48 시간 동안 각 시료를 처리하였다. 과산화수소 1 mM을 2.5 시간 처리하고 세척 후 소태아혈청이 없는 DMEM 배지에서 24 시간 배양 후 WST-1으로 생존율을 측정하여 하기 표 2에 그 결과를 나타내었다.After inoculating 5,000 dermal papilla cells into 96 wells and culturing for 24 hours, each sample was treated in DMEM medium without fetal bovine serum for 48 hours. After treatment with 1 mM hydrogen peroxide for 2.5 hours, washing and culturing in DMEM medium without fetal bovine serum for 24 hours, the viability was measured with WST-1, and the results are shown in Table 2 below.
상기 표 2에서와 같이, 본 발명에 따른 실시예 1 내지 5는 산화스트레스로부터 모유두세포 보호 효능이 뛰어남을 확인하였으며, 특히 실시예 4가 산화스트레스로부터 모유두세포 보호 효능이 뛰어남을 확인하였다.As shown in Table 2, Examples 1 to 5 according to the present invention confirmed that the dermal papilla cell protection efficacy from oxidative stress was excellent, and in particular, Example 4 confirmed that the dermal papilla cell protection efficacy from oxidative stress is excellent.
<< 실험예Experimental example 3> 비듬 생성 억제 활성 측정 3> Measurement of dandruff production inhibitory activity
비듬이란 인체의 신진대사에 의해 생긴 두피의 죽은 세포나 벗겨진 세포들이 두피 피지선의 분비물과 함께 말라붙어서 생긴 각질형태의 덩어리를 말한다. 비듬은 점차 정상 피부와 뚜렷한 경계를 가지며, 통상 가려움과 염증을 수반하는 지루피부염으로까지 진행된다. 따라서 비듬의 생성을 억제하는 물질은 탈모방지 및 두피개선에 효과적으로 작용할 것으로 예상하여 실시예 1 내지 실시예 5의 시료가 비듬생성을 억제하는지 평가하기 위해 비듬균 억제 효능을 평가하였다.Dandruff refers to a keratinous mass formed by the dead or exfoliated cells of the scalp caused by the body's metabolism and dried together with the secretions of the scalp sebaceous glands. Dandruff gradually demarcates from normal skin and progresses to seborrheic dermatitis, usually accompanied by itching and inflammation. Therefore, in order to evaluate whether the sample of Examples 1 to 5 inhibits the generation of dandruff, the dandruff inhibitory efficacy was evaluated in anticipation that the substance inhibiting the generation of dandruff would effectively act in preventing hair loss and improving the scalp.
각 시료의 비듬생성 억제 효능을 확인하기 위해 비듬 원인균 피티로스포름 오발레(Pityrosporum ovlae, ATCC 12087)에 대해 억제효능을 측정하였다. 각 시료를 브로스 희석법(broth dilution method)을 이용하여 배지에 단계적으로 희석하고, 이 희석액에 균을 접종 후, 35℃ 인큐베이터에서 48시간 동안 흔들어 배양시켜 균이 증식하지 못하는 최소저해농도(MIC)를 측정하여, 그 결과를 하기 표 3에 나타내었다. In order to confirm the dandruff generation inhibitory efficacy of each sample, the inhibitory effect was measured against the dandruff causative bacterium Pityrosporum ovlae (ATCC 12087). Each sample is diluted stepwise in the medium using the broth dilution method, and after inoculating the bacteria in this dilution, shake and incubate for 48 hours in an incubator at 35 ° C. was measured, and the results are shown in Table 3 below.
상기 표 3에서와 같이, 본 발명에 따른 실시예 1 내지 5는 비듬생성 억제활성이 뛰어남을 확인하였다.As shown in Table 3, Examples 1 to 5 according to the present invention were confirmed to have excellent dandruff production inhibitory activity.
<< 실험예Experimental example 4> 항염 효능 측정 4> Measurement of anti-inflammatory efficacy
실시예 1 내지 실시예 5의 시료의 항염 효과를 확인하기 위하여, 쥐의 대식세포인 RAW264.7 세포를 ATCC에서 구입하여 이용하였다. 세포의 배양(Cell culture)에 사용된 DMEM/F12(Dulbecco's modified Eagle's medium/ Nutrient Mixture Ham's F12), FBS(fetal bovine serum), L-glutamine, 페니실린-스트렙토마이신 및 인슐린(Insulin)은 Gibco/BRL(USA)에서 구입하였다. 상기 RAW264.7 세포는 DMEM/F12 배지에 10% FBS, 1% 페니실린 스트렙토마이신, 1% L-글루타민 및 20 ㎍/㎖ 인슐린을 첨가한 배양액을 사용하여 배양하였고, 37℃ 습윤한 CO₂배양기(5% CO₂/95% air)에서 배양하였다. 상기 세포가 배양접시의 약 80%가 차게 배양된 후, PBS(pH 7.4)로 세포의 단층을 씻어낸 후 세척하고, 0.25% 트립신 및 2.56 mmol/L EDTA를 처리하여 계대 배양하였다.In order to confirm the anti-inflammatory effect of the samples of Examples 1 to 5, RAW264.7 cells, which are macrophages of mice, were purchased from ATCC and used. DMEM/F12 (Dulbecco's modified Eagle's medium/ Nutrient Mixture Ham's F12), FBS (fetal bovine serum), L-glutamine, penicillin-streptomycin and insulin used for cell culture were Gibco/BRL ( USA). The RAW264.7 cells were cultured in DMEM/F12 medium in which 10% FBS, 1% penicillin streptomycin, 1% L-glutamine, and 20 μg/ml insulin were added, and 37° C. wet CO₂ incubator (5 % CO₂/95% air). After the cells were cultured in about 80% of the culture dish cold, the monolayer of cells was washed with PBS (pH 7.4), washed, and subcultured by treatment with 0.25% trypsin and 2.56 mmol/L EDTA.
각 시료와 LPS를 함께 첨가한 후, 24시간 배양한 뒤, 상기 24시간 배양한 후의 배양액을 수집하여, NO의 분비량을 Griess reagent system(Promega, USA)를 이용하여 측정하였으며, 그 결과를 하단에 나타내었다. 상기 Griess reagent system을 이용한 측정법은 보다 상세하게는 상기 시스템의 제조사인 Promega에서 제공한 실험방법(protocol)에 의하였고, 상기 수집된 세포배양액에 Sulfanilamide solution을 먼저 넣고, NED solution을 넣은 후에, microplate reader를 이용하여 540nm에서 측정하는 방법으로 수행하여, 그 결과를 하기 표 4와 같이 나타내었다.After adding each sample and LPS together, after culturing for 24 hours, the culture solution after culturing for 24 hours was collected, and the amount of NO secretion was measured using the Griess reagent system (Promega, USA), and the results are shown at the bottom. indicated. The measurement method using the Griess reagent system was, in more detail, according to the protocol provided by Promega, the manufacturer of the system. Sulfanilamide solution was first put into the collected cell culture medium, NED solution was put in, and then a microplate reader was performed by a method of measuring at 540 nm using a , and the results are shown in Table 4 below.
상기 표 4에서와 같이, 본 발명에 따른 실시예 1 내지 5는 항염 활성이 뛰어남을 확인하였으며, 특히, 실시예 4의 항염 활성이 뛰어남을 확인하였다.As shown in Table 4, Examples 1 to 5 according to the present invention were confirmed to have excellent anti-inflammatory activity, in particular, it was confirmed that the excellent anti-inflammatory activity of Example 4.
<실험예 5> 항균 효능 측정<Experimental Example 5> Measurement of antibacterial efficacy
실시예 1 내지 실시예 5의 시료에 대한 항균력 효과 검정시험으로 고체 배양 희석법(agar serial dilution method)과 원형여과지법(paper disc method)에 의하여 항균시험을 실시하였다. 실험 균주는 한국생명공학연구원으로부터 분양받았으며, 그람양성균으로 포도상구균(Staphylococcus aureus, KCTC 6910), 그람음성균으로 녹농균(Pseudomonas aeruginosa, KCTC 1637), 대장균(E. coli, KCTC 1039), 효모로는 캔디다 효모(Candida albicans, KCTC 7965), 사상균으로 흑국균 (Aspergillus niger, KCTC 6910) 이상 총 5종의 균주를 사용하였다. As an antibacterial effect test for the samples of Examples 1 to 5, the antibacterial test was performed by the agar serial dilution method and the paper disc method. Experimental strains received pre-sale from the Korea Research Institute of Bioscience and Biotechnology, a Gram-positive staphylococci (Staphylococcus aureus, KCTC 6910), a Gram-negative bacteria Pseudomonas aeruginosa (Pseudomonas aeruginosa, KCTC 1637), Escherichia coli (E. coli, KCTC 1039), a yeast Candida Yeast ( Candida albicans , KCTC 7965 ) and filamentous fungi were used as a total of 5 strains of Heukgukgyun ( Aspergillus niger , KCTC 6910 ) or more.
트립틱소이 배지에 균을 접종하여 37℃에서 24시간 전배양하여 준비하고, 효모의 경우, 포테이토덱스트로스 배지에 균을 접종하여 25℃에서 2일간 전배양하였으며, 사상균은 포테이토 덱스트로스 한천배지에 균을 접종하여 25℃ 배양기에서 7일간 전배양한 후, 도말봉을 이용하여, 배지 표면에 형성된 사상균의 포자를 회수하여 멸균된 식염수에 희석하여 사용하였다. The bacteria were inoculated in the tryptic soy medium and pre-cultured at 37°C for 24 hours, and in the case of yeast, the bacteria were inoculated in a potato dextrose medium and pre-cultured at 25°C for 2 days, and the filamentous bacteria were grown on a potato dextrose agar medium. After inoculating the bacteria and pre-culturing for 7 days in an incubator at 25° C., spores of filamentous fungi formed on the surface of the medium were recovered using a smear and diluted in sterile saline for use.
멸균된 패트리 디쉬에 실험균종 별로 5% 디메틸설폭사이드(DMSO) 함유 생리식염수 용액에 적절한 농도로 희석한 각각의 시료(실시예 1 내지 4)를 2㎖씩 넣고, 5% DMSO 함유 생리식염수 용액을 대조군 시료로 2㎖씩 넣은 후, 각 패트리 디쉬에 멸균하고 48℃로 냉각한 트립틱소이 한천배지 및 포테이토덱스트로스 한천배지를 18㎖씩 첨가하여 교반 후 정치하여 응고시켰다.In a sterile Petri dish, 2 ml of each sample (Examples 1 to 4) diluted to an appropriate concentration in 5% dimethyl sulfoxide (DMSO)-containing physiological saline solution for each experimental strain was added, and 5% DMSO-containing physiological saline solution was added. After adding 2 ml each as a control sample, 18 ml of tryptic soy agar medium and potato dextrose agar medium sterilized and cooled to 48° C. were added to each Petri dish, stirred, and then allowed to solidify.
이후 전배양시킨 각각의 시험균을 세균의 경우 최종농도 약 1 X 106 CFU/㎖ 의 균농도로 각각의 페트리디쉬에 도말하고, 효모의 경우 1 X 105 CFU/㎖, 사상균의 경우 약 1 X 104 CFU/㎖의 균농도로 각각의 페트리디쉬에 도말한다. 각각의 페트리 디쉬는 세균은 37℃에서 24시간 배양하고 효모는 25℃에서 3일간 배양, 사상균은 25℃배양기에서 7일간 배양한 후 각 구획 안에 Colony 형성여부를 관찰하였다.Afterwards, each pre-cultured test bacteria is smeared on each Petri dish at a final concentration of about 1 X 10 6 CFU/ml for bacteria, 1 X 10 5 CFU/ml for yeast, and about 1 for filamentous bacteria X 10 4 Smear on each Petri dish at a bacterial concentration of CFU/ml. In each Petri dish, bacteria were cultured at 37°C for 24 hours, yeast was cultured at 25°C for 3 days, and filamentous fungi were cultured for 7 days in an incubator at 25°C, and colony formation was observed in each compartment.
성장이 되지 않은 평판의 최소시료 농도를 최소저해농도 (MIC, Minimum inhibitory concentration)로 하며, 최소저해농도는 값이 작을수록 항균효과가 높음을 의미한다.The minimum sample concentration of the non-growing plate is the minimum inhibitory concentration (MIC), and the smaller the minimum inhibitory concentration, the higher the antibacterial effect.
항균력시험 결과를 하기 표 5에 나타내었다.The results of the antimicrobial activity test are shown in Table 5 below.
상기 표 5에서와 같이, 본 발명에 따른 실시예 1 내지 5는 항균 활성이 뛰어남을 확인하였다.As shown in Table 5, Examples 1 to 5 according to the present invention were confirmed to have excellent antibacterial activity.
<< 실험예Experimental example 6> 6> 피지분비sebum secretion 억제 효능의 측정 Determination of Inhibitory Efficacy
인체 피지선 세포(sebaceous gland cell)는 진피층 내의 모낭(hair follicle)에서 얻었으며, 분리된 피지선 세포는 0.25% 트립신(Trypsin), 0.05% 에틸렌디아민테트라아세트산(Ethylene Diamene Tetraacetic Acid: EDTA)로 30분간 37℃에서 처리하고, 12% 소태아혈청(fetal bovine serum : FBS)가 함유된 MEM(Eagle's minimum essential medium)으로 트립신을 불활성화 시킨 후, 원심분리를 통해 배지를 제거하였으며, 그 후 KGM(keratinocyte growth medium) 배지에 재분산시켜 60mm 컬쳐용 디쉬에 배양하였다, 계대 배양시 본 실험을 위해 24 웰-플레이트(plate)를 이용하여 웰 당 2X105개 세포를 심는다. 24시간 배양하여 세포가 웰에 고착된 이후 각 웰에 실시예 1 내지 5의 시료를 디메틸설폭사이드(dimethylsulfoxide: DMSO)에 분산시켜 최종 농도 0.1%(w/v) 로 처리하여 72시간을 배양한 후, 생존한 세포의 수를 계산하고, 생성된 피지의 양을 메탄올:클로로포름 추출법을 이용하여 추출 및 측정하여 104 cell당 생성된 총 피지량을 비교하여 피지 생성 억제 정도를 상대 비교하였다. 피지의 추출 방법은 조보울리스 등 (Zoboulis et. al.) (J. Invest. Dermatol.,1991; 24, 69-83)의 방법을 이용하였으며, 메탄올:클로로포름 추출단계, 초음파 파쇄단계, 필터링 단계, 질소 증발 (nitrogen evaporation) 단계를 포함한다. 본 실험 결과를 표 6에 나타내었다.Human sebaceous gland cells were obtained from hair follicles in the dermal layer, and the isolated sebaceous gland cells were treated with 0.25% Trypsin and 0.05% Ethylene Diamene Tetraacetic Acid (EDTA) for 30 minutes. After treatment at ℃, trypsin inactivation with MEM (Eagle's minimum essential medium) containing 12% fetal bovine serum (FBS), the medium was removed by centrifugation, and then KGM (keratinocyte growth medium) and cultured in a 60 mm culture dish. For this experiment during subculture, 2X10 5 cells are planted per well using a 24-well-plate. After the cells were cultured for 24 hours, the samples of Examples 1 to 5 were dispersed in dimethylsulfoxide (DMSO) in each well, treated with a final concentration of 0.1% (w/v), and cultured for 72 hours. Thereafter, the number of surviving cells was counted, and the amount of sebum generated was extracted and measured using methanol:chloroform extraction, and the total amount of sebum generated per 10 4 cells was compared to compare the degree of inhibition of sebum production. The extraction method of sebum was the method of Zoboulis et. al. (J. Invest. Dermatol., 1991; 24, 69-83), methanol: chloroform extraction step, ultrasonic crushing step, filtering step , including a nitrogen evaporation step. Table 6 shows the results of this experiment.
상기 표 6에서와 같이, 본 발명에 따른 실시예 1 내지 5는 피지생성 억제 활성이 뛰어남을 확인하였다.As shown in Table 6, Examples 1 to 5 according to the present invention were confirmed to have excellent sebum production inhibitory activity.
<< 실험예Experimental example 7> 단백질 함량 분석 7> Protein content analysis
각 시료(실시예 1 내지 5)의 단백질 함량을 측정하기 위해 BCA(bicinchoninic acid) 측정법을 수행하였다. BCA 측정법은 단백질이 구리 이온(Cu2+, Cu1+)을 환원시킬 수 있는 성질을 이용한 것으로 단백질에 의해 환원된 구리 이온은 BCA 용액과 반응하여 보라빛의 화합물(Cu+/BCA chromophore)을 생성하게 되는데, 이 보랏빛 화합물은 특정 파장 562㎚에서 최대 흡광도를 보인다. 따라서 단백질의 양이 많을수록 보랏빛 화합물이 더 많이 생기며 562㎚에서 흡광도가 증가함을 이용하여 단백질의 양을 측정하였다. 실험방법은 하기과 같다.In order to measure the protein content of each sample (Examples 1 to 5), a bicinchoninic acid (BCA) measurement method was performed. The BCA measurement method uses the property of a protein to reduce copper ions (Cu 2+ , Cu 1+ ). The copper ions reduced by the protein react with the BCA solution to form a purple compound (Cu + /BCA chromophore). This purple compound shows the maximum absorbance at a specific wavelength of 562 nm. Therefore, as the amount of protein increased, more purple compounds were formed, and the amount of protein was measured using the increase in absorbance at 562 nm. The experimental method is as follows.
우선 마이크로 BCA 단백질 측정 시약 키트(Pierce, cat. no. 23227)를 이용, 각 96마이크로플레이트 웰에 각각 150㎕씩 표준액 또는 희석된 시료를 넣은 후 BCA(bicinchoninic acid) 키트 WR(Working Reagent) 시약을 첨가하여 30초간 격렬히 혼합하였다. 그 후 37℃, 2시간 동안 반응시키고 마이크로플레이트 판독기(UVT-06685, Thermo max, 미국)로 540㎚ 흡광도를 측정하여 검량선을 작성하고 단백질 정량하였다. 결과는 다음과 같다.First, using a micro BCA protein measurement reagent kit (Pierce, cat. no. 23227), put 150 μl of standard solution or diluted sample into each 96 microplate well, and then add BCA (bicinchoninic acid) kit WR (Working Reagent) reagent. was added and mixed vigorously for 30 seconds. Thereafter, the reaction was carried out at 37° C. for 2 hours, and absorbance at 540 nm was measured with a microplate reader (UVT-06685, Thermo max, USA) to prepare a calibration curve and protein quantification. The result is as follows.
<< 실험예Experimental example 8> 구성 아미노산 분석 8> Analysis of constituent amino acids
각 시료(실시예 1 내지 5) 0.2g을 20㎖의 6N HCl에 130℃ 24시간 동안 가수분해 시켜 단백질의 펩타이드 결합을 끊어 유리아미노산으로 만들었다. 그 후 유리 아미노산을 OPA(o-phthalaldehyde, Agilent), FMOC(9-fluorenylmethylchloroformate) 유도체를 사용하여 형광을 띄는 아이소인돌(isoindole)을 형성시킨 후 고속액체크로마토그래피(Agilent Technologies 1200 Series HPLC, Agilent, USA)를 이용한 형광검출기(FLD, Agilent Technologies, USA)에서 아미노산을 검출하였다. 표준물질로 250pM 조성물의 성분 아미노산을 확인하였다. 함량은 하기 표 8에 나타내었다.0.2 g of each sample (Examples 1 to 5) was hydrolyzed in 20 ml of 6N HCl at 130° C. for 24 hours to break the peptide bond of the protein to obtain free amino acids. After that, the free amino acid was formed using a derivative of OPA (o-phthalaldehyde, Agilent) and FMOC (9-fluorenylmethylchloroformate) to form a fluorescent isoindole, followed by high-performance liquid chromatography (Agilent Technologies 1200 Series HPLC, Agilent, USA). ) using a fluorescence detector (FLD, Agilent Technologies, USA) to detect amino acids. As a standard material, the component amino acids of the 250pM composition were identified. The content is shown in Table 8 below.
acid
(ppm)Amino
acid
(ppm)
시
예 line
city
Yes
<제형 제조예> <Formulation Preparation Example> 제형예Formulation example 1 내지 3 및 1 to 3 and 비교제형예Comparative formulation example 1 내지 3의 제조 Preparation of 1 to 3
본 발명에 따른 조성물의 제형에 따른 사용감을 확인해보기 위하여, 하기 표 9의 조성에 따른 탈모방지 헤어 샴푸 조성물 (제형예 1), 하기 표 10의 조성에 따른 탈모방지 헤어 컨디셔너 조성물 (제형예 2) 및 하기 표 11의 조성에 따른 탈모방지 헤어 토닉 조성물 (제형예 3)을 제조하였다.In order to check the feeling of use according to the formulation of the composition according to the present invention, an anti-hair loss hair shampoo composition according to the composition of Table 9 (Formulation Example 1), and an anti-hair loss hair conditioner composition according to the composition of Table 10 (Formulation Example 2) And an anti-hair loss hair tonic composition (Formulation Example 3) according to the composition of Table 11 was prepared.
또한, 본 발명에 따른 제형예와 비교하기 위하여, 하기 표 12의 조성에 따른 In addition, in order to compare with the formulation example according to the present invention, according to the composition of Table 12
일반 샴푸 조성물 (비교제형예 1), 하기 표 13의 조성에 따른 일반 탈모방지 헤어 컨디셔너 조성물 (비교제형예 2) 및 하기 표 14의 조성에 따른 일반 탈모방지 헤어 토닉 조성물 (비교제형예 3)을 제조하였다.A general shampoo composition (Comparative Formulation Example 1), a general anti-hair loss hair conditioner composition according to the composition of Table 13 (Comparative Formulation Example 2) and a general anti-hair loss hair tonic composition according to the composition of Table 14 (Comparative Formulation Example 3) prepared.
<< 실험예Experimental example 9> 샴푸 제형의 9> Shampoo formulation 사용감feeling 테스트 test
대학교 재학생 30명을 대상으로 두 그룹으로 나누어 4주간 해당 제형에 대해 사용감 테스트를 진행하였다. 1주일에 3회 이상 제품을 사용하도록 하였으며 총 6주 동안 사용 후 설문조사를 실시하였다. 설문조사 척도는 다음과 같이 진행하였다.30 university students were divided into two groups, and a feeling test was conducted on the formulation for 4 weeks. The product was to be used at least 3 times a week, and a survey was conducted after use for a total of 6 weeks. The survey scale was conducted as follows.
5점 : 아주 좋음/ 4점 : 좋음/ 3점 : 보통/ 2점 : 효과 없음/ 1점 : 악화5 points: very good/ 4 points: good/ 3 points: average/ 2 points: no effect/ 1 point: poor
본 발명에 따른 제형예 1 내지 3과 이에 대응하는 비교제형예 1 내지 3에 대하여 비교 사용감 테스트 후 설문조사를 실시한 결과는 하기 표 15 내지 17과 같다.The results of the questionnaire after the comparative usability test for Formulation Examples 1 to 3 according to the present invention and Comparative Formulation Examples 1 to 3 corresponding thereto are shown in Tables 15 to 17 below.
설문조사 결과 본 발명에 따른 조성물을 투입하지 않은 제형보다 투입한 제형에서 높은 점수를 받는 경향을 확인하였으며 이를 통해 본 발명에 따른 조성물을 투입하였을 때 임상적인 효과가 있음을 확인하였다.As a result of the survey, it was confirmed that the formulation according to the present invention received a higher score than the formulation in which the composition according to the present invention was not added.
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적 기술은 단지 바람직한 실시태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.As the specific parts of the present invention have been described in detail above, for those of ordinary skill in the art, these specific descriptions are only preferred embodiments, and it is clear that the scope of the present invention is not limited thereby. something to do. Accordingly, it is intended that the substantial scope of the present invention be defined by the appended claims and their equivalents.
Claims (16)
상기 혼합 추출물은 맥문동, 백자인, 만형자, 향부자, 감국, 상백피, 천궁, 백지, 세신, 측백엽, 한련초, 생강 및 인삼에 물을 첨가한 후 95℃ 내지 100℃의 온도로 추출하여 수득한 열수 추출물에 에틸아세테이트를 첨가하여 분리되는 에틸아세테이트 분획을 제거한 다음, 에틸아세테이트 분획으로 분리되지 않은 분획에 부탄올을 첨가하여 분리되는 부탄올 분획물인 것을 특징으로 하는, 화장료 조성물.A cosmetic composition comprising, as an active ingredient, a mixed extract of maekmundong extract, white jasmine extract, manhyeongja extract, hyangbuja extract, chrysanthemum extract, chrysanthemum extract, cheongung extract, white paper extract, sessin extract, arborvitae extract, orchid extract, ginger extract and ginseng extract as,
The mixed extract is a hot water extract obtained by adding water to maekmundong, white jain, manhyeongja, hyangbuja, gamguk, sangbaekpi, cheongung, white paper, sesin, chrysanthemum, chrysanthemum, ginger and ginseng, followed by extraction at a temperature of 95°C to 100°C. A cosmetic composition, characterized in that it is a butanol fraction separated by adding ethyl acetate to remove the ethyl acetate fraction, and then adding butanol to the fraction not separated into the ethyl acetate fraction.
상기 맥문동 추출물의 함량은 조성물의 전체 중량에 대하여, 0.01중량% 내지 10중량%인 것을 특징으로 하는, 화장료 조성물.According to claim 1,
The content of the maekmundong extract is, with respect to the total weight of the composition, a cosmetic composition, characterized in that 0.01% to 10% by weight.
상기 백자인 추출물, 만형자 추출물, 향부자 추출물, 감국 추출물, 상백피 추출물, 천궁 추출물, 백지 추출물, 세신 추출물, 측백엽 추출물, 한련초 추출물, 생강 추출물 및 인삼 추출물의 총 함량은 조성물의 전체 중량에 대하여, 0.01중량% 내지 10중량%인 것을 특징으로 하는, 화장료 조성물.According to claim 1,
The total content of the white ginseng extract, manhyeongja extract, hyangbuja extract, chrysanthemum extract, sangbaekpi extract, cheongung extract, white paper extract, sesin extract, arborvitae extract, orchid extract, ginger extract, and ginseng extract is 0.01 weight based on the total weight of the composition % to 10% by weight, the cosmetic composition.
상기 조성물은 탈모방지 또는 두피개선용인 것을 특징으로 하는, 화장료 조성물.According to claim 1,
The composition is a cosmetic composition, characterized in that for preventing hair loss or improving the scalp.
상기 조성물은 항산화용인 것을 특징으로 하는, 화장료 조성물.According to claim 1,
The composition is characterized in that for antioxidant, cosmetic composition.
상기 조성물은 항비듬용인 것을 특징으로 하는, 화장료 조성물.According to claim 1,
The composition is characterized in that for anti-dandruff, cosmetic composition.
상기 조성물은 항균용인 것을 특징으로 하는, 화장료 조성물.According to claim 1,
The composition is characterized in that for antibacterial, cosmetic composition.
상기 조성물은 피지 분비 억제용인 것을 특징으로 하는, 화장료 조성물.According to claim 1,
The composition is a cosmetic composition, characterized in that for inhibiting sebum secretion.
상기 조성물은 항염용인 것을 특징으로 하는, 화장료 조성물.According to claim 1,
The composition is characterized in that for anti-inflammatory, cosmetic composition.
상기 혼합 추출물은 백자인 추출물, 만형자 추출물, 향부자 추출물, 감국 추출물, 상백피 추출물, 천궁 추출물, 백지 추출물, 세신 추출물, 측백엽 추출물, 한련초 추출물, 생강 추출물 및 인삼 추출물로 이루어진 혼합물과 맥문동 추출물을 12:1의 중량비로 혼합한 것임을 특징으로 하는, 화장료 조성물.According to claim 1,
The mixed extract is a mixture consisting of white ginseng extract, manhyeongja extract, hyangbuja extract, chrysanthemum extract, sangbaekpi extract, cheongung extract, white paper extract, sessin extract, arborvitae extract, chrysanthemum extract, ginger extract and ginseng extract and maekmundong extract 12:1 A cosmetic composition, characterized in that it is mixed in a weight ratio of
상기 맥문동 추출물, 백자인 추출물, 만형자 추출물, 향부자 추출물, 감국 추출물, 상백피 추출물, 천궁 추출물, 백지 추출물, 세신 추출물, 측백엽 추출물, 한련초 추출물, 생강 추출물 및 인삼 추출물의 중량비는 1:1:1:1:1:1:1:1:1:1:1:1:1인 것을 특징으로 하는, 화장료 조성물.According to claim 1,
The weight ratio of the maekmundong extract, white ginseng extract, manhyeongja extract, hyangbuja extract, chrysanthemum extract, sangbaekpi extract, cheongung extract, white paper extract, sesin extract, arborvitae extract, chrysanthemum extract, ginger extract and ginseng extract is 1:1:1:1 1:1:1:1:1:1:1:1:1:1, a cosmetic composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150153435A KR102324672B1 (en) | 2015-11-02 | 2015-11-02 | Composition comprising extract from liriope platyphylla and natural extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150153435A KR102324672B1 (en) | 2015-11-02 | 2015-11-02 | Composition comprising extract from liriope platyphylla and natural extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170051077A KR20170051077A (en) | 2017-05-11 |
KR102324672B1 true KR102324672B1 (en) | 2021-11-11 |
Family
ID=58741802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150153435A KR102324672B1 (en) | 2015-11-02 | 2015-11-02 | Composition comprising extract from liriope platyphylla and natural extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102324672B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109674722B (en) * | 2019-01-31 | 2021-08-03 | 广州艾蓓生物科技有限公司 | Anti-hair-loss and hair-growing essence and preparation method thereof |
WO2023282726A1 (en) * | 2021-07-09 | 2023-01-12 | 이정호 | Oriental medicine composition having hair loss prevention and hair growth effect |
-
2015
- 2015-11-02 KR KR1020150153435A patent/KR102324672B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
Asian Journal of Beauty and Cosmetology, 제12권, 제6호, 773-786쪽, 2014년 12월 공개* |
BioIn, 탈모예방 및 발모 관련 화장품 특허동향. [online], (2003.04.11.공개)* |
Also Published As
Publication number | Publication date |
---|---|
KR20170051077A (en) | 2017-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101059471B1 (en) | Cosmetic composition for skin aging | |
KR101017709B1 (en) | Cosmetic composition comprising the herbal mixed extract comprising panax ginseng c.a meyer showing hair-growth stimulating activity and preventing activity from hair loss | |
JP3407935B2 (en) | External preparation for skin | |
KR20200088074A (en) | Skin external composition comprising centella asiatica extract and papaver rhoeas extract | |
KR101541533B1 (en) | Cosmetic composition for preventing fall-out of hair, growing hair, preventing of generating dandruff and relieving inflammation of scalp | |
KR101390465B1 (en) | Method for Preparing Paeonia lactiflora Extracts Containing Taxifolin-3-glucoside and Cosmetic Composition Containing Preparing Paeonia lactiflora Extracts | |
KR102130571B1 (en) | Low irritating cosmetic composition for skin whitening comprising albutin and extract of Euterpe oleracea fruit | |
KR101397160B1 (en) | Cosmetic compositon for skin-irritation alleviation with Inula britannica var. chinensis, Cynanchi Radix and Lysimachia foenum-graecum Hance | |
KR20160023149A (en) | Composition comprising extract of herbal mixture for preventing alopecia or hair growth effect | |
KR102324672B1 (en) | Composition comprising extract from liriope platyphylla and natural extract | |
KR20140018666A (en) | Composition for skin external application containing fermented soybean extract | |
JP3648730B2 (en) | Skin cosmetics | |
KR101954275B1 (en) | Cosmetic compositions containing complex extract of gold kiwi peel and dragon fruit peel, and method manufacturing the same | |
KR20150112103A (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
KR20210009178A (en) | Compositions containing Gastrodia extracts | |
KR102198589B1 (en) | Whitening cosmetic composition containing Rhodiola rosea, Selaginella tamariscina, Celosia cristata and Artemisia princeps complex extract and phytol | |
KR102477053B1 (en) | Cosmetic composition comprising an extract of a mixture comprising baked glycyrrhiza uralensis fisch, cyperus rotundus l. and curcuma longa l. | |
KR102373899B1 (en) | Multifunctional cosmetic composition containing complex natural extracts effective for skin wrinkle improvement, whitening, cell regeneration, and wound healing as an active ingredient | |
KR102199858B1 (en) | Cosmetic Compositions Comprising Complex Extracts of Oriental Medicinal Herbs | |
KR101793104B1 (en) | Cosmetic composition for whitening skin comprising mixed extract of Cudrania tricuspidata leaf and Morus alba leaf as effective component | |
KR102090008B1 (en) | Cosmetic Composition for Preventing Hair Loss Containing Plumcot Extract | |
KR101317433B1 (en) | The cosmetic composition for skin whitening comprising the mixture of extract of Hovenia dulcia, Platycodon grandiflorum, wheat bud and sage | |
KR20210071395A (en) | Cosmetic composition for promoting hair growth containing extracts of moringa oleifera and annona muricata as active ingredient | |
KR101131685B1 (en) | Cosmetic compositions having sebosuppressive effect | |
KR102692058B1 (en) | A cosmetic composition for anti-oxidation, anti-inflammation, and anti-dandruff comrising brassica oleracea italica extract, apium graveolens extract and spinacia oleracea extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |